DDD Partners LLC Sells 126,370 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

DDD Partners LLC cut its holdings in ARK Genomic Revolution ETF (BATS:ARKG) by 81.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 28,447 shares of the company’s stock after selling 126,370 shares during the period. DDD Partners LLC’s holdings in ARK Genomic Revolution ETF were worth $670,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ARKG. Sanctuary Advisors LLC bought a new stake in shares of ARK Genomic Revolution ETF in the second quarter worth approximately $222,000. Crescent Grove Advisors LLC grew its position in ARK Genomic Revolution ETF by 1.6% in the 3rd quarter. Crescent Grove Advisors LLC now owns 28,914 shares of the company’s stock worth $740,000 after purchasing an additional 460 shares during the period. Prospera Financial Services Inc raised its stake in ARK Genomic Revolution ETF by 18.2% during the 3rd quarter. Prospera Financial Services Inc now owns 33,607 shares of the company’s stock valued at $860,000 after buying an additional 5,180 shares during the last quarter. Captrust Financial Advisors bought a new position in shares of ARK Genomic Revolution ETF during the 3rd quarter valued at $485,000. Finally, PFM Health Sciences LP purchased a new position in shares of ARK Genomic Revolution ETF in the 3rd quarter worth $2,226,000.

ARK Genomic Revolution ETF Price Performance

ARK Genomic Revolution ETF stock opened at $29.42 on Monday. The firm’s 50 day moving average price is $25.54 and its two-hundred day moving average price is $25.24.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.